CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.93 and traded as high as $5.66. CASI Pharmaceuticals shares last traded at $5.49, with a volume of 10,524 shares changing hands.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of CASI Pharmaceuticals in a research note on Saturday, August 3rd. They issued a "hold" rating for the company.
Read Our Latest Report on CASI Pharmaceuticals
CASI Pharmaceuticals Stock Up 6.0 %
The stock has a market cap of $78.13 million, a P/E ratio of -2.56 and a beta of 0.69. The firm has a 50 day simple moving average of $6.21 and a 200-day simple moving average of $4.93. The company has a quick ratio of 2.36, a current ratio of 3.88 and a debt-to-equity ratio of 2.05.
CASI Pharmaceuticals (NASDAQ:CASI - Get Free Report) last announced its quarterly earnings results on Friday, August 16th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11. CASI Pharmaceuticals had a negative return on equity of 126.20% and a negative net margin of 118.81%. The business had revenue of $3.98 million during the quarter, compared to the consensus estimate of $4.43 million.
Institutional Trading of CASI Pharmaceuticals
An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC raised its position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI - Free Report) by 10.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,800 shares of the biotechnology company's stock after acquiring an additional 4,000 shares during the period. Renaissance Technologies LLC owned approximately 0.30% of CASI Pharmaceuticals worth $224,000 at the end of the most recent quarter. Institutional investors and hedge funds own 22.23% of the company's stock.
About CASI Pharmaceuticals
(
Get Free Report)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
See Also
Before you consider CASI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CASI Pharmaceuticals wasn't on the list.
While CASI Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
